Evommune CFO sells shares after option exercise
Evommune, Inc. Chief Financial Officer Kyle Carver reported an option exercise and related share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Evommune, Inc. Chief Financial Officer Kyle Carver reported an option exercise and related share sale. On May 28, he exercised options to acquire 15,000 shares of common stock at $2.99 per share and sold 18,175 shares of common stock in open-market transactions at a weighted average price of $22.84 per share.
The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the sale, Carver directly holds 59,335 shares of Evommune common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Carver Kyle
Role
Chief Financial Officer
Sold
18,175 shs ($415K)
Approx. gross sale proceeds
$415K
Approx. exercise cost
$45K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $2.99 | $45K |
| Sale | Common Stock | 18,175 | $22.84 | $415K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 96,731 contracts (Direct);
Common Stock — 59,335 shares (Direct)
Footnotes (3)
- F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.
- F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Shares sold: 18,175 shares
Sale price: $22.84/share
Sale price range: $22.50–$23.42
+5 more
8 metrics
Shares sold
18,175 shares
Common stock sold on May 28, 2026 in open market
Sale price
$22.84/share
Weighted average sale price for 18,175 shares
Sale price range
$22.50–$23.42
Price range for multiple sale transactions
Options exercised
15,000 shares
Employee Stock Option (Right to Buy) exercised
Option exercise price
$2.99/share
Conversion or exercise price of stock option
Shares held after sale
59,335 shares
Common stock beneficially owned following transactions
10b5-1 plan adoption date
February 26, 2026
Date CFO adopted Rule 10b5-1 trading plan
Option expiration
December 8, 2034
Expiration date of Employee Stock Option
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Evommune (EVMN) report for its CFO?
Evommune reported that CFO Kyle Carver exercised options for 15,000 shares at $2.99 and sold 18,175 common shares at a weighted average of $22.84 per share. These trades were disclosed in a Form 4 insider transaction filing.
What options did the Evommune (EVMN) CFO exercise in this Form 4?
The CFO exercised an Employee Stock Option for 15,000 underlying common shares at a conversion or exercise price of $2.99 per share. The option is titled “Employee Stock Option (Right to Buy)” and relates directly to Evommune common stock.
What is the vesting schedule for the Evommune (EVMN) CFO’s stock option?
A footnote explains that one fourth of the option shares vest on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly installments. Vesting is conditioned on the CFO’s continuous service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates